However, in CLDs, a decrease in these transporters has been observed due to an inhibition in FXR signaling by the subunit NF-κβ p65 binding directly to FXR, which inhibits its transcriptional activity, thus maintaining liver inflammation and the probable development of HCC[74]. This evidence concerns the gene NR1H4 and hepatocellular carcinoma.